1. INTRODUCTION
1.1. Market Overview
1.3. Market Definition
1.4. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Powers of Buyers
4.3.3. Threat of Substitutes
4.3.4. The Threat of New Entrants
4.3.5. Competitive Rivalry in Industry
4.4. Industry Value Chain Analysis
5. EUROPE ANTIBODY-DRUG CONJUGATES MARKET BY TARGET
5.1. CD
305.2. CD
225.3. HER
26. EUROPE ANTIBODY-DRUG CONJUGATES MARKET BY INDICATION
6.1. Haematologic Malignancies
6.2. Non-Haematologic Malignancies
7. EUROPE ANTIBODY-DRUG CONJUGATES MARKET BY COUNTRY
7.1. Germany
7.2. France
7.3. UK
7.4. Others
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Vendor Matrix and Analysis
8.2. Recent Investments and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. Takeda Pharmaceutical Company Limited
9.2. F. Hoffmann-La Roche Ltd.
9.3. Pfizer Inc.
9.4. Synthon Holding B.V.
9.5. Immunomedics GmbH
9.6. Biotest AG
9.7. Astellas Pharma Inc.
9.8. Seattle Genetics, Inc.